Amalgamated Bank increased its position in shares of Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 1.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,307 shares of the biopharmaceutical company’s stock after acquiring an additional 561 shares during the quarter. Amalgamated Bank’s holdings in Royalty Pharma were worth $1,474,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Captrust Financial Advisors raised its position in Royalty Pharma by 210.8% during the second quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 546 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Royalty Pharma in the third quarter valued at $39,000. CI Investments Inc. lifted its position in Royalty Pharma by 79.4% in the third quarter. CI Investments Inc. now owns 965 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 427 shares during the period. Mendota Financial Group LLC acquired a new stake in Royalty Pharma during the fourth quarter worth $57,000. Finally, Hikari Tsushin Inc. increased its holdings in Royalty Pharma by 469.2% in the 4th quarter. Hikari Tsushin Inc. now owns 2,220 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 1,830 shares during the period. Hedge funds and other institutional investors own 55.36% of the company’s stock.
Insider Transactions at Royalty Pharma
In related news, EVP George W. Lloyd sold 100,000 shares of the stock in a transaction that occurred on Tuesday, March 28th. The stock was sold at an average price of $37.06, for a total transaction of $3,706,000.00. Following the completion of the sale, the executive vice president now directly owns 225,000 shares of the company’s stock, valued at approximately $8,338,500. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Royalty Pharma news, Director Rory B. Riggs sold 1,750,000 shares of the firm’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $32.82, for a total transaction of $57,435,000.00. Following the completion of the sale, the director now directly owns 6,762 shares in the company, valued at $221,928.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP George W. Lloyd sold 100,000 shares of Royalty Pharma stock in a transaction that occurred on Tuesday, March 28th. The shares were sold at an average price of $37.06, for a total transaction of $3,706,000.00. Following the completion of the sale, the executive vice president now owns 225,000 shares of the company’s stock, valued at $8,338,500. The disclosure for this sale can be found here. Insiders have sold a total of 1,859,926 shares of company stock valued at $61,507,766 over the last three months. 24.86% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Royalty Pharma Trading Down 0.3 %
Shares of NASDAQ RPRX opened at $33.31 on Tuesday. The company’s 50 day simple moving average is $34.86 and its 200 day simple moving average is $37.33. The firm has a market capitalization of $20.22 billion, a P/E ratio of 60.56, a P/E/G ratio of 0.91 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.36 and a quick ratio of 2.36. Royalty Pharma plc has a fifty-two week low of $32.02 and a fifty-two week high of $44.66.
Royalty Pharma Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Investors of record on Friday, May 19th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 2.40%. The ex-dividend date of this dividend is Thursday, May 18th. Royalty Pharma’s payout ratio is 145.45%.
Royalty Pharma Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Articles
- Get a free copy of the StockNews.com research report on Royalty Pharma (RPRX)
- Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
- Sleeper AI-Play MongoDB Could Triple In Size
- SunCar Technology Stock Overheats…Will it Rise Again?
- OPEC Meeting: Is Saudi Arabia Trying to Squeeze the Oil Market?
- Buffett-Backed BYD Caught In The Chinese Government’s Stimulus
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma plc (NASDAQ:RPRX – Get Rating).
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
